BioCentury
ARTICLE | Company News

Advent to acquire Sanofi's EU generics business

April 20, 2018 7:08 PM UTC

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion).

Last year, Sanofi indicated it was looking to divest Zentiva as part of its “strategic roadmap 2020" aimed at simplifying its organization...